International Stem Cell Corporation (OTCQB: ISCO) is a Montreal-based company devoted to developing its novel and innovative proprietary technologies for enhanced drug delivery. Through its cutting edge formulation platforms, the company has developed a broad and diverse product portfolio, including products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. For more information, visit the company’s website at www.hecla-mining.com.